264277-38-5

Basic information

• Product Name: tert-butyl N-[(1S)-3-hydroxy-1-[[(3R)-tetrahydrofuran-3-yl]carbamoyl] propyl] carbamate
• Synonyms: tert-butyl N-[(1S)-3-hydroxy-1-[[(3R)-tetrahydrofuran-3-yl]carbamoyl] propyl] carbamate
• CAS NO: 264277-38-5
• Molecular Weight: 288.344
• Mol File: 264277-38-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tert-butyl N-[(1S)-3-hydroxy-1-[[(3R)-tetrahydrofuran-3-yl]carbamoyl] propyl] carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-[(1S)-3-hydroxy-1-[[(3R)-tetrahydrofuran-3-yl]carbamoyl] propyl] carbamate(264277-38-5)
• EPA Substance Registry System: tert-butyl N-[(1S)-3-hydroxy-1-[[(3R)-tetrahydrofuran-3-yl]carbamoyl] propyl] carbamate(264277-38-5)

Safety Data

• Hazardous Substances Data: 264277-38-5(Hazardous Substances Data)

Upstream product

• 40856-59-5 tert-butyl (3S)-2-oxotetrahydrofuran-3-ylcarbamate 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.